BPC-157

BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice, marketed for tendon, ligament, and gut healing. Animal studies suggest pro-angiogenic and tissue-repair effects, but human clinical-trial data are very limited, comprising only a small number of pilot studies with no large well-controlled RCTs. It is not approved by the FDA or EMA. Injectable BPC-157 was placed on the FDA 503A Category 2 (significant safety concerns) interim bulk drug substances list and was removed from Category 2 on 22 April 2026 alongside eleven other peptides whose nominators withdrew, pending a Pharmacy Compounding Advisory Committee (PCAC) review scheduled for 23–24 July 2026; this is not an approval, and BPC-157 remains unauthorised for any therapeutic indication and prohibited at all times under WADA category S0 (Unapproved Substances).